ReP USP - Resultado da busca

Artigo de periodico
Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant (2024)
Marques, Rodolfo Ferreira ; Gimenez, Alba Marina ; Caballero, Otávia; Simpson, Andrew; Salazar, Andres M; Amino, Rogerio ; Godin, Steven; Gazzinelli, Ricardo T, ; Soares, Irene da Silva
Fonte: Vaccine. Unidades: ICB, FCF
Assuntos: MALÁRIA, VACINAS, PLASMODIUM
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARQUES, Rodolfo Ferreira et al. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant. Vaccine, v. 42, n. 9, p. 2394-2406, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.vaccine.2024.02.070. Acesso em: 01 nov. 2024.
APA
Marques, R. F., Gimenez, A. M., Caballero, O., Simpson, A., Salazar, A. M., Amino, R., et al. (2024). Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant. Vaccine, 42( 9), 2394-2406. doi:10.1016/j.vaccine.2024.02.070
NLM
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares I da S. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant [Internet]. Vaccine. 2024 ; 42( 9): 2394-2406.[citado 2024 nov. 01 ] Available from: https://dx.doi.org/10.1016/j.vaccine.2024.02.070
Vancouver
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares I da S. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant [Internet]. Vaccine. 2024 ; 42( 9): 2394-2406.[citado 2024 nov. 01 ] Available from: https://dx.doi.org/10.1016/j.vaccine.2024.02.070
Artigo de periodico
In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial (2024)
Fonseca, Henrique Andrade R; Zimerman, Andre; Monfardini, Frederico; Guimaraes, Helio Penna; Pedrosa, Rodrigo P; Patriota, Rodrigo de Lemos S; Patriota, Tarcya L. G. Couto; Passos, Luiz Carlos Santana; Dall'orto, Frederico Toledo Campo; Nicolau, Jose Carlos
Fonte: Vaccine. Unidade: FM
Assuntos: VACINAÇÃO, SÍNDROME CORONARIANA AGUDA, MORTALIDADE, INFLUENZA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Henrique Andrade R et al. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial. Vaccine, v. 42, n. 3, p. 496-504, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58827. Acesso em: 01 nov. 2024.
APA
Fonseca, H. A. R., Zimerman, A., Monfardini, F., Guimaraes, H. P., Pedrosa, R. P., Patriota, R. de L. S., et al. (2024). In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial. Vaccine, 42( 3), 496-504. doi:10.1016/j.vaccine.2023.12.074
NLM
Fonseca HAR, Zimerman A, Monfardini F, Guimaraes HP, Pedrosa RP, Patriota R de LS, Patriota TLGC, Passos LCS, Dall'orto FTC, Nicolau JC. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial [Internet]. Vaccine. 2024 ; 42( 3): 496-504.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58827
Vancouver
Fonseca HAR, Zimerman A, Monfardini F, Guimaraes HP, Pedrosa RP, Patriota R de LS, Patriota TLGC, Passos LCS, Dall'orto FTC, Nicolau JC. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial [Internet]. Vaccine. 2024 ; 42( 3): 496-504.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58827
Artigo de periodico
Vaccine value profile for cytomegalovirus (2023)
Boppana, Suresh B.; van Boven, Michiel; Britt, William J.; Gantt, Soren; Griffiths, Paul D.; Grosse, Scott D.; Hyde, Terri B.; Lanzieri, Tatiana M.; Mussi-Pinhata, Marisa Márcia ; Pallas, Sarah E.; Pinninti, Swetha G.; Rawlinson, William D.; Ross, Sharon Ann; Vossen, Ann C. T. M.; Fowler, Karen B.
Fonte: Vaccine. Unidade: FMRP
Assuntos: CITOMEGALOVIRUS, VACINAS, DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOPPANA, Suresh B. et al. Vaccine value profile for cytomegalovirus. Vaccine, v. 41, p. S53-S75, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2023.06.020. Acesso em: 01 nov. 2024.
APA
Boppana, S. B., van Boven, M., Britt, W. J., Gantt, S., Griffiths, P. D., Grosse, S. D., et al. (2023). Vaccine value profile for cytomegalovirus. Vaccine, 41, S53-S75. doi:10.1016/j.vaccine.2023.06.020
NLM
Boppana SB, van Boven M, Britt WJ, Gantt S, Griffiths PD, Grosse SD, Hyde TB, Lanzieri TM, Mussi-Pinhata MM, Pallas SE, Pinninti SG, Rawlinson WD, Ross SA, Vossen ACTM, Fowler KB. Vaccine value profile for cytomegalovirus [Internet]. Vaccine. 2023 ; 41 S53-S75.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2023.06.020
Vancouver
Boppana SB, van Boven M, Britt WJ, Gantt S, Griffiths PD, Grosse SD, Hyde TB, Lanzieri TM, Mussi-Pinhata MM, Pallas SE, Pinninti SG, Rawlinson WD, Ross SA, Vossen ACTM, Fowler KB. Vaccine value profile for cytomegalovirus [Internet]. Vaccine. 2023 ; 41 S53-S75.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2023.06.020
Artigo de periodico
The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies (2023)
Soarez, Patricia Coelho De ; Rozmana, Luciana Martins ; Fonseca, Taiane Siraisi; Borsari, Pietro Rodrigo; Percio, Jadher ; Barrera, Lely Stella Guzman; Sartori, Ana Marli Christovam
Fonte: Vaccine. Unidade: FM
Assuntos: REVISÃO SISTEMÁTICA, CUSTOS DOS CUIDADOS DE SAÚDE, SARAMPO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOAREZ, Patricia Coelho De et al. The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies. Vaccine, v. 41, n. 7, p. 1319-1332, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54767. Acesso em: 01 nov. 2024.
APA
Soarez, P. C. D., Rozmana, L. M., Fonseca, T. S., Borsari, P. R., Percio, J., Barrera, L. S. G., & Sartori, A. M. C. (2023). The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies. Vaccine, 41( 7), 1319-1332. doi:10.1016/j.vaccine.2023.01.015
NLM
Soarez PCD, Rozmana LM, Fonseca TS, Borsari PR, Percio J, Barrera LSG, Sartori AMC. The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies [Internet]. Vaccine. 2023 ; 41( 7): 1319-1332.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54767
Vancouver
Soarez PCD, Rozmana LM, Fonseca TS, Borsari PR, Percio J, Barrera LSG, Sartori AMC. The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies [Internet]. Vaccine. 2023 ; 41( 7): 1319-1332.[citado 2024 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54767
Artigo de periodico
Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021–2022 data (2023)
Boing, Antonio Fernando ; Boing, Alexandra Crispim ; Barberia, Lorena ; Borges, Marcelo Eduardo; Subramanian, S.V.
Fonte: Vaccine. Unidade: FFLCH
Assuntos: VACINAÇÃO, FATORES SOCIOECONÔMICOS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOING, Antonio Fernando et al. Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021–2022 data. Vaccine, v. 41, n. 26, p. 3937-3945, 2023Tradução . . Disponível em: https://biblio.fflch.usp.br/Boing_AC_3166571_UncoveringInequalitiesInCovid19VaccineCoverageForAdultsAndElderlyInBrazil.pdf. Acesso em: 01 nov. 2024.
APA
Boing, A. F., Boing, A. C., Barberia, L., Borges, M. E., & Subramanian, S. V. (2023). Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021–2022 data. Vaccine, 41( 26), 3937-3945. doi:10.1016/j.vaccine.2023.05.030
NLM
Boing AF, Boing AC, Barberia L, Borges ME, Subramanian SV. Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021–2022 data [Internet]. Vaccine. 2023 ; 41( 26): 3937-3945.[citado 2024 nov. 01 ] Available from: https://biblio.fflch.usp.br/Boing_AC_3166571_UncoveringInequalitiesInCovid19VaccineCoverageForAdultsAndElderlyInBrazil.pdf
Vancouver
Boing AF, Boing AC, Barberia L, Borges ME, Subramanian SV. Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: a multilevel study of 2021–2022 data [Internet]. Vaccine. 2023 ; 41( 26): 3937-3945.[citado 2024 nov. 01 ] Available from: https://biblio.fflch.usp.br/Boing_AC_3166571_UncoveringInequalitiesInCovid19VaccineCoverageForAdultsAndElderlyInBrazil.pdf
Artigo de periodico
BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial (2022)
Dionato, Franciele Aparecida Vecchia ; Buosi, Keini ; Visacri, Marilia Berlofa ; Dal Col, Luciana S. B ; Giacomelli, Cristiane F; Leme, Patricia A. F; Maia, Cristiane L; Moriel, Patricia ; Reis, Leonardo Oliveira
Fonte: Vaccine. Unidade: FCF
Assuntos: ESTUDOS RANDOMIZADOS, VACINAS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DIONATO, Franciele Aparecida Vecchia et al. BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial. Vaccine, v. 40, p. 4603–4608, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2022.06.039. Acesso em: 01 nov. 2024.
APA
Dionato, F. A. V., Buosi, K., Visacri, M. B., Dal Col, L. S. B., Giacomelli, C. F., Leme, P. A. F., et al. (2022). BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial. Vaccine, 40, 4603–4608. doi:10.1016/j.vaccine.2022.06.039
NLM
Dionato FAV, Buosi K, Visacri MB, Dal Col LSB, Giacomelli CF, Leme PAF, Maia CL, Moriel P, Reis LO. BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial [Internet]. Vaccine. 2022 ; 40 4603–4608.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2022.06.039
Vancouver
Dionato FAV, Buosi K, Visacri MB, Dal Col LSB, Giacomelli CF, Leme PAF, Maia CL, Moriel P, Reis LO. BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial [Internet]. Vaccine. 2022 ; 40 4603–4608.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2022.06.039
Artigo de periodico
A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates (2022)
Ribeiro, Susan Pereira; Mattaraia, Vania Gomes de Moura; Almeida, Rafael Ribeiro ; Valentine, Elizabeth Juliana Ghiuro; Sales, Natiely Silva; Ferreira, Luís Carlos de Souza ; Sá-Rocha, Luiz Carlos de ; Jacintho, Lucas Cauê; Santana, Vinicius Canato; Sidney, John; Sette, Alessandro; Rosa, Daniela Santoro ; Kalil Filho, Jorge Elias ; Cunha Neto, Edecio
Fonte: Vaccine. Unidades: ICB, FMVZ, FM
Assuntos: VACINAS VIRAIS, HIV, LINFÓCITOS T, EPITOPOS, PRIMATAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Susan Pereira et al. A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. Vaccine, v. 40, n. 2, p. 239-246, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2021.11.076. Acesso em: 01 nov. 2024.
APA
Ribeiro, S. P., Mattaraia, V. G. de M., Almeida, R. R., Valentine, E. J. G., Sales, N. S., Ferreira, L. C. de S., et al. (2022). A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. Vaccine, 40( 2), 239-246. doi:10.1016/j.vaccine.2021.11.076
NLM
Ribeiro SP, Mattaraia VG de M, Almeida RR, Valentine EJG, Sales NS, Ferreira LC de S, Sá-Rocha LC de, Jacintho LC, Santana VC, Sidney J, Sette A, Rosa DS, Kalil Filho JE, Cunha Neto E. A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates [Internet]. Vaccine. 2022 ; 40( 2): 239-246.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2021.11.076
Vancouver
Ribeiro SP, Mattaraia VG de M, Almeida RR, Valentine EJG, Sales NS, Ferreira LC de S, Sá-Rocha LC de, Jacintho LC, Santana VC, Sidney J, Sette A, Rosa DS, Kalil Filho JE, Cunha Neto E. A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates [Internet]. Vaccine. 2022 ; 40( 2): 239-246.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2021.11.076
Artigo de periodico
Efficacy of commercially available vaccines against canine leptospirosis: a systematic review and meta-analysis (2022)
Esteves, Stephanie Bergmann; Santos, Cassia Moreira; Salgado, Fabiana Ferreira; Gonçales, Amane Paldês ; Guilloux, Aline Gil Alves ; Martins, Camila Marinelli ; Hagiwara, Mitika Kuribaiashi; Miotto, Bruno Alonso
Fonte: Vaccine. Unidades: FMVZ, FM
Assuntos: CÃES, LEPTOSPIROSE ANIMAL, VACINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ESTEVES, Stephanie Bergmann et al. Efficacy of commercially available vaccines against canine leptospirosis: a systematic review and meta-analysis. Vaccine, v. 40, n. 12, p. 1722-1740, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2022.02.021. Acesso em: 01 nov. 2024.
APA
Esteves, S. B., Santos, C. M., Salgado, F. F., Gonçales, A. P., Guilloux, A. G. A., Martins, C. M., et al. (2022). Efficacy of commercially available vaccines against canine leptospirosis: a systematic review and meta-analysis. Vaccine, 40( 12), 1722-1740. doi:10.1016/j.vaccine.2022.02.021
NLM
Esteves SB, Santos CM, Salgado FF, Gonçales AP, Guilloux AGA, Martins CM, Hagiwara MK, Miotto BA. Efficacy of commercially available vaccines against canine leptospirosis: a systematic review and meta-analysis [Internet]. Vaccine. 2022 ; 40( 12): 1722-1740.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2022.02.021
Vancouver
Esteves SB, Santos CM, Salgado FF, Gonçales AP, Guilloux AGA, Martins CM, Hagiwara MK, Miotto BA. Efficacy of commercially available vaccines against canine leptospirosis: a systematic review and meta-analysis [Internet]. Vaccine. 2022 ; 40( 12): 1722-1740.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2022.02.021
Artigo de periodico
Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination (2021)
Nunes, Altacilio Aparecido ; Abreu, Ariane de Jesus Lopes de ; Cintra, Otávio; Cintra, Monica Akissue de Camargo Teixeira; Coelho, Eduardo Barbosa ; Barros, Eliana Nogueira Castro de
Fonte: Vaccine. Unidade: FMRP
Assuntos: EPIDEMIOLOGIA, MENINGITE, SAÚDE PÚBLICA, VACINAÇÃO, IMUNIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NUNES, Altacilio Aparecido et al. Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination. Vaccine, v. 39, n. 3, p. 605-616, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.11.067. Acesso em: 01 nov. 2024.
APA
Nunes, A. A., Abreu, A. de J. L. de, Cintra, O., Cintra, M. A. de C. T., Coelho, E. B., & Barros, E. N. C. de. (2021). Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination. Vaccine, 39( 3), 605-616. doi:10.1016/j.vaccine.2020.11.067
NLM
Nunes AA, Abreu A de JL de, Cintra O, Cintra MA de CT, Coelho EB, Barros ENC de. Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination [Internet]. Vaccine. 2021 ; 39( 3): 605-616.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.11.067
Vancouver
Nunes AA, Abreu A de JL de, Cintra O, Cintra MA de CT, Coelho EB, Barros ENC de. Meningococcal disease epidemiology in Brazil (2005–2018) and impact of MenC vaccination [Internet]. Vaccine. 2021 ; 39( 3): 605-616.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.11.067
Artigo de periodico
CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions (2021)
Fradico, Jordana Rodrigues Barbosa; Campi-Azevedo, Ana Carolina; Magalhães, Vanessa Peruhype; Coelho-dos-Reis, Jordana Grazziela Alves; Faria, Elaine Spezialli; Drumond, Betânia Paiva; Rezende, Izabela Maurício de; Almeida, Janaina Fonseca; Silva, Roberta Barros da; Gusmão, Josiane Dias; Fernandes, Eder Gatti; Martins, Maria Auxiliadora; Valim, Valeria
Fonte: Vaccine. Unidades: FM, FMRP
Assuntos: QUIMIOCINAS, INTERLEUCINA 1, VACINAÇÃO, FEBRE AMARELA, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRADICO, Jordana Rodrigues Barbosa et al. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions. Vaccine, v. 39, n. 31, p. 4359–4372, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2021.05.101. Acesso em: 01 nov. 2024.
APA
Fradico, J. R. B., Campi-Azevedo, A. C., Magalhães, V. P., Coelho-dos-Reis, J. G. A., Faria, E. S., Drumond, B. P., et al. (2021). CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions. Vaccine, 39( 31), 4359–4372. doi:10.1016/j.vaccine.2021.05.101
NLM
Fradico JRB, Campi-Azevedo AC, Magalhães VP, Coelho-dos-Reis JGA, Faria ES, Drumond BP, Rezende IM de, Almeida JF, Silva RB da, Gusmão JD, Fernandes EG, Martins MA, Valim V. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions [Internet]. Vaccine. 2021 ; 39( 31): 4359–4372.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2021.05.101
Vancouver
Fradico JRB, Campi-Azevedo AC, Magalhães VP, Coelho-dos-Reis JGA, Faria ES, Drumond BP, Rezende IM de, Almeida JF, Silva RB da, Gusmão JD, Fernandes EG, Martins MA, Valim V. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions [Internet]. Vaccine. 2021 ; 39( 31): 4359–4372.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2021.05.101
Artigo de periodico
Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil (2020)
Fernandes, Eder Gatti; Sartori, Ana Marli Christovam ; Soarez, Patricia Coelho de ; Amaku, Marcos ; Azevedo Neto, Raymundo Soares de ; Novaes, Hillegonda Maria Dutilh
Fonte: Vaccine. Unidade: FM
Assuntos: CUSTOS DOS CUIDADOS DE SAÚDE, IMUNIZAÇÃO, CAMPANHAS DE VACINAÇÃO, TÉTANO, DIFTERIA, COQUELUCHE, ADULTOS, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Eder Gatti et al. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine, v. 38, n. 1, p. 46-53, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2019.09.100. Acesso em: 01 nov. 2024.
APA
Fernandes, E. G., Sartori, A. M. C., Soarez, P. C. de, Amaku, M., Azevedo Neto, R. S. de, & Novaes, H. M. D. (2020). Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil. Vaccine, 38( 1), 46-53. doi:10.1016/j.vaccine.2019.09.100
NLM
Fernandes EG, Sartori AMC, Soarez PC de, Amaku M, Azevedo Neto RS de, Novaes HMD. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil [Internet]. Vaccine. 2020 ; 38( 1): 46-53.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.09.100
Vancouver
Fernandes EG, Sartori AMC, Soarez PC de, Amaku M, Azevedo Neto RS de, Novaes HMD. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil [Internet]. Vaccine. 2020 ; 38( 1): 46-53.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.09.100
Artigo de periodico
Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses (2020)
Amaral, Marcelo Pires ; Apostolico, Juliana de Souza ; Tomita, Nádia ; Coirada, Fernanda Caroline ; Lunardelli, Victória Alves Santos; Fernandes, Edgar Ruz ; Souza, Higo Fernando Santos ; Astray, Renato Mancini ; Boscardin, Silvia Beatriz ; Rosa, Daniela Santoro
Fonte: Vaccine. Unidade: ICB
Assuntos: PARASITOLOGIA, ZIKA VÍRUS, ADJUVANTES IMUNOLÓGICOS, VACINAS VIRAIS, GLICOPROTEÍNAS, PROTEÍNAS DA MEMBRANA, CAMUNDONGOS, DNA RECOMBINANTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AMARAL, Marcelo Pires et al. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. Vaccine, v. 38, n. 20, p. 3653-3664, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.03.037. Acesso em: 01 nov. 2024.
APA
Amaral, M. P., Apostolico, J. de S., Tomita, N., Coirada, F. C., Lunardelli, V. A. S., Fernandes, E. R., et al. (2020). Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. Vaccine, 38( 20), 3653-3664. doi:10.1016/j.vaccine.2020.03.037
NLM
Amaral MP, Apostolico J de S, Tomita N, Coirada FC, Lunardelli VAS, Fernandes ER, Souza HFS, Astray RM, Boscardin SB, Rosa DS. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses [Internet]. Vaccine. 2020 ; 38( 20): 3653-3664.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.03.037
Vancouver
Amaral MP, Apostolico J de S, Tomita N, Coirada FC, Lunardelli VAS, Fernandes ER, Souza HFS, Astray RM, Boscardin SB, Rosa DS. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses [Internet]. Vaccine. 2020 ; 38( 20): 3653-3664.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.03.037
Artigo de periodico
Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection (2020)
Uziel, Yosef; Moshe, Veronica; Onozo, Beata; Kulcsár, Andrea; Tróbert-Sipos, Diána; Akikusa, Jonathan D.; Pileggi, Gecilmara Cristina Salviato; Maritsi, Despoina; Kasapcopur, Ozgur; Rodrigues, Mariana; Smerla, Roubini; Rigante, Donato; Makay, Balahan; Atsali, Erato; Wulffraat, Nico; Toplak, Nataša
Fonte: Vaccine. Unidade: FMRP
Assuntos: VACINAS, VACINAÇÃO, CRIANÇAS, SEGURANÇA DO PACIENTE, IMUNOSSUPRESSÃO, DOENÇAS REUMÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
UZIEL, Yosef et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine, v. 38, n. 9, p. 2198-2201, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.01.037. Acesso em: 01 nov. 2024.
APA
Uziel, Y., Moshe, V., Onozo, B., Kulcsár, A., Tróbert-Sipos, D., Akikusa, J. D., et al. (2020). Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine, 38( 9), 2198-2201. doi:10.1016/j.vaccine.2020.01.037
NLM
Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Pileggi GCS, Maritsi D, Kasapcopur O, Rodrigues M, Smerla R, Rigante D, Makay B, Atsali E, Wulffraat N, Toplak N. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection [Internet]. Vaccine. 2020 ; 38( 9): 2198-2201.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.01.037
Vancouver
Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Pileggi GCS, Maritsi D, Kasapcopur O, Rodrigues M, Smerla R, Rigante D, Makay B, Atsali E, Wulffraat N, Toplak N. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection [Internet]. Vaccine. 2020 ; 38( 9): 2198-2201.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.01.037
Artigo de periodico
Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation and remodelling in an animal model of mite-induced respiratory allergy (2020)
Aun, Marcelo Vivolo ; Almeida, Francine Maria de; Saraiva-Romanholo, Beatriz Mangueira ; Martins, Milton de Arruda ; Kalil Filho, Jorge Elias ; Arantes-costa, Fernanda Magalhaes; Giavina-Bianchi Júnior, Pedro Francisco
Fonte: Vaccine. Unidade: FM
Assuntos: ASMA, VACINAS, DIFTERIA, TÉTANO, COQUELUCHE, CAMUNDONGOS, ÁCAROS, HIPERSENSIBILIDADE, IMUNOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AUN, Marcelo Vivolo et al. Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation and remodelling in an animal model of mite-induced respiratory allergy. Vaccine, v. 38, n. 1, p. 70-78, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2019.09.095. Acesso em: 01 nov. 2024.
APA
Aun, M. V., Almeida, F. M. de, Saraiva-Romanholo, B. M., Martins, M. de A., Kalil Filho, J. E., Arantes-costa, F. M., & Giavina-Bianchi Júnior, P. F. (2020). Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation and remodelling in an animal model of mite-induced respiratory allergy. Vaccine, 38( 1), 70-78. doi:10.1016/j.vaccine.2019.09.095
NLM
Aun MV, Almeida FM de, Saraiva-Romanholo BM, Martins M de A, Kalil Filho JE, Arantes-costa FM, Giavina-Bianchi Júnior PF. Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation and remodelling in an animal model of mite-induced respiratory allergy [Internet]. Vaccine. 2020 ; 38( 1): 70-78.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.09.095
Vancouver
Aun MV, Almeida FM de, Saraiva-Romanholo BM, Martins M de A, Kalil Filho JE, Arantes-costa FM, Giavina-Bianchi Júnior PF. Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation and remodelling in an animal model of mite-induced respiratory allergy [Internet]. Vaccine. 2020 ; 38( 1): 70-78.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.09.095
Artigo de periodico
An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design (2020)
V, C. Herst; Burkholz, S; Sidney, J; Sette, A; Harris, P. E; Massey, S; Brasel, T; Cunha Neto, Edecio ; Rosa, D. S; Chao, W. C. H
Fonte: Vaccine. Unidade: FM
Assuntos: EPITOPOS, IMUNIDADE, MORBIDADE, VACINAÇÃO, SOBREVIDA, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
V, C. Herst et al. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine, v. 38, n. 28, p. 4464-4475, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.04.034. Acesso em: 01 nov. 2024.
APA
V, C. H., Burkholz, S., Sidney, J., Sette, A., Harris, P. E., Massey, S., et al. (2020). An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. Vaccine, 38( 28), 4464-4475. doi:10.1016/j.vaccine.2020.04.034
NLM
V CH, Burkholz S, Sidney J, Sette A, Harris PE, Massey S, Brasel T, Cunha Neto E, Rosa DS, Chao WCH. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design [Internet]. Vaccine. 2020 ; 38( 28): 4464-4475.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.04.034
Vancouver
V CH, Burkholz S, Sidney J, Sette A, Harris PE, Massey S, Brasel T, Cunha Neto E, Rosa DS, Chao WCH. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design [Internet]. Vaccine. 2020 ; 38( 28): 4464-4475.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.04.034
Artigo de periodico
The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015 (2020)
Silveira, Mariangela F; Buffarini, Romina; Bertoldi, Andrea D; Santos, Ina S; Barros, Aluisio J. D; Manitto, Alicia Matijasevich ; Menezes, Ana Maria B; Goncalves, Helen; Horta, Bernardo L; Barros, Fernando C
Fonte: Vaccine. Unidade: FM
Assuntos: VACINAÇÃO, FATORES SOCIOECONÔMICOS, ESTUDOS DE COORTES, PROGRAMAS DE VACINAÇÃO, FINANCIAMENTO DA ASSISTÊNCIA À SAÚDE, ADESÃO À MEDICAÇÃO, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVEIRA, Mariangela F et al. The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015. Vaccine, v. 38, n. 3, p. 482-488, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2019.10.070. Acesso em: 01 nov. 2024.
APA
Silveira, M. F., Buffarini, R., Bertoldi, A. D., Santos, I. S., Barros, A. J. D., Manitto, A. M., et al. (2020). The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015. Vaccine, 38( 3), 482-488. doi:10.1016/j.vaccine.2019.10.070
NLM
Silveira MF, Buffarini R, Bertoldi AD, Santos IS, Barros AJD, Manitto AM, Menezes AMB, Goncalves H, Horta BL, Barros FC. The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015 [Internet]. Vaccine. 2020 ; 38( 3): 482-488.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.10.070
Vancouver
Silveira MF, Buffarini R, Bertoldi AD, Santos IS, Barros AJD, Manitto AM, Menezes AMB, Goncalves H, Horta BL, Barros FC. The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts, 1982-2015 [Internet]. Vaccine. 2020 ; 38( 3): 482-488.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.10.070
Artigo de periodico
Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: a randomized study (2020)
Nakasone, Mayumi; Lopes, Marta Heloísa ; Sartori, Ana Marli Chritovam; Sandoval, Eliane Partite Nobre; Villaca, Paula Ribeiro; D'amico, Elbio Antonio; Carneiro, Jorge David Aivazoglou
Fonte: Vaccine. Unidade: FM
Assuntos: HEMOFILIA, HEMORRAGIA, HEPATITE A
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NAKASONE, Mayumi et al. Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: a randomized study. Vaccine, v. 38, n. 26, p. 4162-4166, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.04.040. Acesso em: 01 nov. 2024.
APA
Nakasone, M., Lopes, M. H., Sartori, A. M. C., Sandoval, E. P. N., Villaca, P. R., D'amico, E. A., & Carneiro, J. D. A. (2020). Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: a randomized study. Vaccine, 38( 26), 4162-4166. doi:10.1016/j.vaccine.2020.04.040
NLM
Nakasone M, Lopes MH, Sartori AMC, Sandoval EPN, Villaca PR, D'amico EA, Carneiro JDA. Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: a randomized study [Internet]. Vaccine. 2020 ; 38( 26): 4162-4166.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.04.040
Vancouver
Nakasone M, Lopes MH, Sartori AMC, Sandoval EPN, Villaca PR, D'amico EA, Carneiro JDA. Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: a randomized study [Internet]. Vaccine. 2020 ; 38( 26): 4162-4166.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.04.040
Artigo de periodico
Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization (2020)
Santos, Nayara Fernanda Barros dos; Silva, Lukas Raposo da; Costa, Fagner James Martins Dantas; Mattos, Daniely Maranhão de; Carvalho, Enéas de ; Ferreira, Luís Carlos de Souza ; Ferreira, Rita de Cássia Café
Fonte: Vaccine. Unidades: ICB, BIOTECNOLOGIA
Assuntos: MICROBIOLOGIA, IMUNIZAÇÃO, PROTEÍNAS RECOMBINANTES, IMUNIDADE, CAMUNDONGOS, STREPTOCOCCUS, ANTIBIÓTICOS, VACINAS, RESISTÊNCIA MICROBIANA ÀS DROGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Nayara Fernanda Barros dos et al. Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization. Vaccine, v. 38, n. 33, p. 5286-5296, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.05.076. Acesso em: 01 nov. 2024.
APA
Santos, N. F. B. dos, Silva, L. R. da, Costa, F. J. M. D., Mattos, D. M. de, Carvalho, E. de, Ferreira, L. C. de S., & Ferreira, R. de C. C. (2020). Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization. Vaccine, 38( 33), 5286-5296. doi:10.1016/j.vaccine.2020.05.076
NLM
Santos NFB dos, Silva LR da, Costa FJMD, Mattos DM de, Carvalho E de, Ferreira LC de S, Ferreira R de CC. Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization [Internet]. Vaccine. 2020 ; 38( 33): 5286-5296.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.05.076
Vancouver
Santos NFB dos, Silva LR da, Costa FJMD, Mattos DM de, Carvalho E de, Ferreira LC de S, Ferreira R de CC. Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization [Internet]. Vaccine. 2020 ; 38( 33): 5286-5296.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.05.076
Artigo de periodico
Safety of yellow fever vaccine administration in confirmed egg-allergic patients (2020)
Gerhardt, Clarissa Morais Busatto; Castro, Ana Paula Beltran Moschione; Pastorino, Antonio Carlos; Dorna, Mayra de Barros; Nunes-Santos, Cristiane de Jesus; Aquilante, Bruna Pultrini; Miyaji, Karina Takesaki; Lopes, Marta Heloísa
Fonte: Vaccine. Unidade: FM
Assuntos: ESTUDOS PROSPECTIVOS, TESTES CUTÂNEOS, FEBRE AMARELA, PREVENÇÃO E CONTROLE, VACINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GERHARDT, Clarissa Morais Busatto et al. Safety of yellow fever vaccine administration in confirmed egg-allergic patients. Vaccine, v. 38, n. 42, p. 6539-6544, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2020.08.020. Acesso em: 01 nov. 2024.
APA
Gerhardt, C. M. B., Castro, A. P. B. M., Pastorino, A. C., Dorna, M. de B., Nunes-Santos, C. de J., Aquilante, B. P., et al. (2020). Safety of yellow fever vaccine administration in confirmed egg-allergic patients. Vaccine, 38( 42), 6539-6544. doi:10.1016/j.vaccine.2020.08.020
NLM
Gerhardt CMB, Castro APBM, Pastorino AC, Dorna M de B, Nunes-Santos C de J, Aquilante BP, Miyaji KT, Lopes MH. Safety of yellow fever vaccine administration in confirmed egg-allergic patients [Internet]. Vaccine. 2020 ; 38( 42): 6539-6544.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.08.020
Vancouver
Gerhardt CMB, Castro APBM, Pastorino AC, Dorna M de B, Nunes-Santos C de J, Aquilante BP, Miyaji KT, Lopes MH. Safety of yellow fever vaccine administration in confirmed egg-allergic patients [Internet]. Vaccine. 2020 ; 38( 42): 6539-6544.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2020.08.020
Artigo de periodico
Association between the timing of maternal vaccination and newborns? anti-pertussis toxin antibody levels (2019)
Vaz de Lima, Lourdes Rehder de Andrade; Castilho, Euclides A. de; Sato, Helena Keico; Fernandes, Eder Gatti; Sato, Ana Paula Sayuri ; Pawloski, Lúcia C; Tondella, Maria Lúcia; Brito, Cyro A. de; Luna, Expedito José de Albuquerque; Carvalhanas, Telma Regina M.P
Fonte: Vaccine. Unidades: FM, FSP, IMT
Assuntos: SAÚDE MATERNO-INFANTIL, COQUELUCHE, VACINAÇÃO, ANTICORPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VAZ DE LIMA, Lourdes Rehder de Andrade et al. Association between the timing of maternal vaccination and newborns? anti-pertussis toxin antibody levels. Vaccine, v. 37, n. 36, p. 5474-5480, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2019.04.079. Acesso em: 01 nov. 2024.
APA
Vaz de Lima, L. R. de A., Castilho, E. A. de, Sato, H. K., Fernandes, E. G., Sato, A. P. S., Pawloski, L. C., et al. (2019). Association between the timing of maternal vaccination and newborns? anti-pertussis toxin antibody levels. Vaccine, 37( 36), 5474-5480. doi:10.1016/j.vaccine.2019.04.079
NLM
Vaz de Lima LR de A, Castilho EA de, Sato HK, Fernandes EG, Sato APS, Pawloski LC, Tondella ML, Brito CA de, Luna EJ de A, Carvalhanas TRMP. Association between the timing of maternal vaccination and newborns? anti-pertussis toxin antibody levels [Internet]. Vaccine. 2019 ;37( 36): 5474-5480.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.04.079
Vancouver
Vaz de Lima LR de A, Castilho EA de, Sato HK, Fernandes EG, Sato APS, Pawloski LC, Tondella ML, Brito CA de, Luna EJ de A, Carvalhanas TRMP. Association between the timing of maternal vaccination and newborns? anti-pertussis toxin antibody levels [Internet]. Vaccine. 2019 ;37( 36): 5474-5480.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.vaccine.2019.04.079

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

País de publicação

Agência de fomento

Indexado em

Afiliação dos autores externos normalizada

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos